Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 14/20 | 0.51 |
| ▸ | HCAR3 | P49019 | 9/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | DHODH | Q02127 | 1/20 | 0.35 |
| ▸ | CFTR | P13569 | 1/20 | 0.34 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4500250 | 1.00 | HCAR2 (0.51) | HCAR2HCAR3CYP1A2SIRT1KDM4E | |
| SCHEMBL4503649 | 1.00 | HCAR2 (0.51) | HCAR2HCAR3CYP1A2SIRT1KDM4E | |
| SCHEMBL4502815 | 0.75 | KDM4E (0.48) | HCAR2HCAR3CYP1A2SIRT1KDM4E | |
| SCHEMBL4509101 | 0.75 | KDM4E (0.48) | HCAR2HCAR3CYP1A2SIRT1KDM4E | |
| SCHEMBL4496221 | 0.75 | KDM4E (0.48) | HCAR2HCAR3CYP1A2SIRT1KDM4E | |
| SCHEMBL28548234 | 0.73 | HCAR2 (0.53) | HCAR2HCAR3CYP1A2SIRT1MMP2 | |
| SCHEMBL6926535 | 0.72 | HCAR2 (0.49) | HCAR2HCAR3CYP1A2SIRT1KDM4E | |
| SCHEMBL7556814 | 0.70 | HCAR2 (0.51) | HCAR2HCAR3CYP1A2SIRT1MMP2 | |
| SCHEMBL5316374 | 0.69 | — | — | |
| SCHEMBL8125015 | 0.68 | HCAR2 (0.62) | HCAR2HCAR3CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612099-B2 | Vinylogous acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-11-03 | — | — | US | disclosed |
| EP-1957483-A1 | NOVEL VINYLOGOUS ACIDS DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007063010-A1 | NOVEL VINYLOGOUS ACIDS DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-07 | — | — | WO | disclosed |
| US-20070129421-A1 | Vinylogous acid derivatives | HOFFMANN-LA ROCHE INC. | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129421-A1 | Vinylogous acid derivatives | CMA1, TPSG1, TPSAB1 | HCAR2 484/4885HCAR3 295/4885CYP1A2 488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.